ADMA Other Assets vs Other Liab Analysis
| ADMA Stock | USD 21.30 0.07 0.33% |
ADMA Biologics financial indicator trend analysis is way more than just evaluating ADMA Biologics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ADMA Biologics is a good investment. Please check the relationship between ADMA Biologics Other Assets and its Other Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
Other Assets vs Other Liab
Other Assets vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ADMA Biologics Other Assets account and Other Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between ADMA Biologics' Other Assets and Other Liab is 0.42. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Other Liab in the same time period over historical financial statements of ADMA Biologics, assuming nothing else is changed. The correlation between historical values of ADMA Biologics' Other Assets and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of ADMA Biologics are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Other Assets i.e., ADMA Biologics' Other Assets and Other Liab go up and down completely randomly.
Correlation Coefficient | 0.42 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Other Assets
Other Liab
Most indicators from ADMA Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 226.09, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 79.8M | 118.8M | 170.0M | 178.5M | Research Development | 3.6M | 3.6M | 3.3M | 4.4M |
ADMA Biologics fundamental ratios Correlations
Click cells to compare fundamentals
ADMA Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ADMA Biologics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 127.1M | 207.7M | 276.3M | 348.5M | 329.2M | 345.6M | |
| Short Long Term Debt Total | 84.7M | 97.7M | 102.9M | 154.4M | 141.4M | 148.5M | |
| Total Current Liabilities | 14.0M | 19.9M | 30.4M | 39.3M | 49.8M | 52.3M | |
| Net Debt | 58.0M | 41.7M | 51.8M | 67.9M | 90.1M | 94.6M | |
| Cash | 26.8M | 55.9M | 51.1M | 86.5M | 51.4M | 27.8M | |
| Common Stock Shares Outstanding | 54.3M | 86.1M | 139.6M | 197.9M | 224.0M | 235.2M | |
| Liabilities And Stockholders Equity | 127.1M | 207.7M | 276.3M | 348.5M | 329.2M | 345.6M | |
| Total Liab | 100.9M | 119.4M | 135.1M | 196.5M | 194.0M | 203.7M | |
| Total Current Assets | 85.8M | 153.7M | 208.7M | 270.4M | 257.0M | 269.9M | |
| Other Current Liab | 4.5M | 8.0M | 17.2M | 25.1M | 32.9M | 34.6M | |
| Total Stockholder Equity | 26.2M | 88.2M | 141.2M | 152.0M | 135.2M | 142.0M | |
| Cash And Short Term Investments | 26.8M | 55.9M | 51.1M | 86.5M | 51.4M | 29.7M | |
| Common Stock Total Equity | 5.9K | 10.5K | 19.6K | 22.2K | 20.0K | 19.0K | |
| Non Current Liabilities Total | 86.9M | 99.5M | 104.7M | 157.2M | 144.2M | 151.4M | |
| Other Stockholder Equity | 290.9M | 428.7M | 553.3M | 630.0M | 641.4M | 673.5M | |
| Common Stock | 5.9K | 10.5K | 19.6K | 22.2K | 23K | 29.8K | |
| Retained Earnings | (264.7M) | (340.5M) | (412.1M) | (478.0M) | (506.3M) | (480.9M) | |
| Property Plant And Equipment Net | 31.7M | 45.9M | 58.2M | 68.7M | 63.5M | 66.6M | |
| Accounts Payable | 9.2M | 11.1M | 12.4M | 13.2M | 15.7M | 16.4M | |
| Non Current Assets Total | 41.3M | 53.9M | 67.5M | 78.1M | 72.2M | 75.8M | |
| Other Assets | 2.8M | 6.4M | 4.1M | 4.8M | 1.0 | 0.95 | |
| Net Receivables | 3.5M | 13.2M | 28.6M | 15.5M | 27.4M | 28.8M | |
| Inventory | 53.1M | 81.5M | 124.7M | 163.3M | 172.9M | 181.6M | |
| Other Current Assets | 2.5M | 6.1M | 4.3M | 10.2M | 5.3M | 2.8M | |
| Property Plant And Equipment Gross | 31.7M | 45.9M | 50.9M | 58.3M | 90.2M | 94.7M | |
| Non Currrent Assets Other | 2.8M | 2.1M | 4.1M | 4.8M | 4.7M | 4.9M | |
| Other Liab | 2.4M | 2.2B | 2.4M | 3.7M | 4.2M | 4.0M | |
| Net Tangible Assets | 19.5M | 82.3B | 141.2M | 152.0M | 174.8M | 166.0M | |
| Long Term Debt | 68.3M | 93.0M | 94.9M | 142.8M | 130.6M | 137.1M | |
| Retained Earnings Total Equity | (264.7M) | (340.5M) | (412.1M) | (478.0M) | (430.2M) | (408.7M) | |
| Capital Surpluse | 290.9M | 428.7M | 553.3M | 630.0M | 724.5M | 760.7M | |
| Capital Lease Obligations | 1.3M | 4.7M | 8.1M | 11.6M | 10.8M | 11.4M | |
| Non Current Liabilities Other | 15.0M | 54.9K | 397.4K | 1.9M | 2.1M | 2.0M | |
| Short Term Debt | 229.1K | 731.4K | 591.1K | 905K | 1.0M | 1.2M | |
| Intangible Assets | 3.2M | 2.4M | 1.7M | 1.0M | 499K | 474.1K | |
| Property Plant Equipment | 31.7M | 45.9B | 50.9M | 58.3M | 67.0M | 63.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.